Ciprofol as compared to propofol for sedation and general anesthesia : a systematic review of randomized controlled trials
© 2024. The Author(s)..
BACKGROUND: Propofol is the most commonly used hypnotic agent used during sedation and general anesthesia (GA) practice, offering faster recovery compared to benzodiazepines. However, cardiovascular impact of propofol and pain at injection are commonly encountered side effects. Ciprofol is a novel disubstituted phenol derivative, and there is growing evidence regarding its clinical use.
METHODS: We conducted a systematic literature search (updated on 23 July 2023) to evaluate safety and efficacy of ciprofol in comparison to propofol in patients undergoing procedures under sedation or GA. We focused on randomized controlled trials (RCTs) only, extrapolating data on onset and offset, and on the side effects and the pain at injection.
RESULTS: The search revealed 14 RCTs, all conducted in China. Eight RCTs studied patients undergoing sedation, and six focused on GA. Bolus of ciprofol for sedation or induction of GA varied from 0.2 to 0.5 mg/kg. In four studies using ciprofol for maintenance of GA, it was 0.8-2.4 mg/kg/h. Ciprofol pharmacokinetics seemed characterized by slower onset and offset as compared to propofol. Pain during injection was less frequent in the ciprofol group in all the 13 studies reporting it. Eight studies reported "adverse events" as a pooled outcome, and in five cases, the incidence was higher in the propofol group, not different in the remaining ones. Occurrence of hypotension was the most commonly investigated side effects, and it seemed less frequent with ciprofol.
CONCLUSION: Ciprofol for sedation or GA may be safer than propofol, though its pharmacokinetics may be less advantageous.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Journal of anesthesia, analgesia and critical care - 4(2024), 1 vom: 08. Apr., Seite 24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Currò, Jessica M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benzodiazepines |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s44158-024-00159-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370792645 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370792645 | ||
| 003 | DE-627 | ||
| 005 | 20240410233011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s44158-024-00159-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370792645 | ||
| 035 | |a (NLM)38589912 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Currò, Jessica M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ciprofol as compared to propofol for sedation and general anesthesia |b a systematic review of randomized controlled trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Propofol is the most commonly used hypnotic agent used during sedation and general anesthesia (GA) practice, offering faster recovery compared to benzodiazepines. However, cardiovascular impact of propofol and pain at injection are commonly encountered side effects. Ciprofol is a novel disubstituted phenol derivative, and there is growing evidence regarding its clinical use | ||
| 520 | |a METHODS: We conducted a systematic literature search (updated on 23 July 2023) to evaluate safety and efficacy of ciprofol in comparison to propofol in patients undergoing procedures under sedation or GA. We focused on randomized controlled trials (RCTs) only, extrapolating data on onset and offset, and on the side effects and the pain at injection | ||
| 520 | |a RESULTS: The search revealed 14 RCTs, all conducted in China. Eight RCTs studied patients undergoing sedation, and six focused on GA. Bolus of ciprofol for sedation or induction of GA varied from 0.2 to 0.5 mg/kg. In four studies using ciprofol for maintenance of GA, it was 0.8-2.4 mg/kg/h. Ciprofol pharmacokinetics seemed characterized by slower onset and offset as compared to propofol. Pain during injection was less frequent in the ciprofol group in all the 13 studies reporting it. Eight studies reported "adverse events" as a pooled outcome, and in five cases, the incidence was higher in the propofol group, not different in the remaining ones. Occurrence of hypotension was the most commonly investigated side effects, and it seemed less frequent with ciprofol | ||
| 520 | |a CONCLUSION: Ciprofol for sedation or GA may be safer than propofol, though its pharmacokinetics may be less advantageous | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Benzodiazepines | |
| 650 | 4 | |a Hypnosis | |
| 650 | 4 | |a Nonoperating room anesthesia | |
| 650 | 4 | |a Operating room | |
| 650 | 4 | |a Propofol | |
| 700 | 1 | |a Santonocito, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Merola, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Sanfilippo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Brancati, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Drago, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Sanfilippo, Filippo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of anesthesia, analgesia and critical care |d 2021 |g 4(2024), 1 vom: 08. Apr., Seite 24 |w (DE-627)NLM357760298 |x 2731-3786 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2024 |g number:1 |g day:08 |g month:04 |g pages:24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s44158-024-00159-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2024 |e 1 |b 08 |c 04 |h 24 | ||